Rural ambulatory care pharmacists providing in-clinic and home visit services improve adherence to long-acting injectable antipsychotics
- PMID: 38835813
- PMCID: PMC11147658
- DOI: 10.9740/mhc.2024.06.229
Rural ambulatory care pharmacists providing in-clinic and home visit services improve adherence to long-acting injectable antipsychotics
Abstract
Patients with schizophrenia often experience symptoms such as poor insight and disorganized thought, which limit their ability to seek and receive care consistently. In rural settings, systemic factors, including limited resources and transportation, further contribute to difficulties in health care access. Long-acting injectable antipsychotics (LAIs) can improve medication adherence and reduce hospitalizations from relapse. Opportunities exist for pharmacists to provide individualized care and improved health care access. The pilot service took place in ambulatory care clinics and home care settings. Pharmacists performed weekly reviews of patients with active orders for LAIs, coordinated care with nonadherent patients, and offered follow-up appointments in the Patient Centered Medical Home (PCMH). For patients unable to be reached, outreach pharmacists provided psychiatric assessment and LAI medication administration at home visits. There were 10 patients with LAI prescriptions in the past year selected for review. The period reviewed was 90 days before and after start of service. Pharmacist interventions resulted in 4 patients reestablished with care who were previously lost to follow-up. The percentage of days covered by LAI fills increased from an average 26% to 67% of days covered (P = .06). Total emergency room visits related to mental health episodes decreased from 11 to 2 visits (P = .03). Four patients who did not have metabolic lab monitoring in more than 1 year received lab monitoring as indicated. PCMH pharmacy services, including home visits by outreach pharmacists, may improve access and bridge care gaps for patients on LAIs by providing community-based services in addition to traditional clinic-based care.
Keywords: CMM; LAI antipsychotics; access; adherence; barriers; community; innovative; long-acting injectable; outreach; rural; schizophrenia.
© 2024 AAPP. The Mental Health Clinician is a publication of the American Association of Psychiatric Pharmacists.
Figures
Similar articles
-
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.Clin Ther. 2017 Oct;39(10):1972-1985.e2. doi: 10.1016/j.clinthera.2017.08.008. Epub 2017 Sep 15. Clin Ther. 2017. PMID: 28919292
-
Assessing need for pharmacist involvement to improve care coordination for patients on LAI antipsychotics transitioning from hospital to home: A work system approach.Res Social Adm Pharm. 2017 Sep-Oct;13(5):1004-1013. doi: 10.1016/j.sapharm.2017.02.006. Res Social Adm Pharm. 2017. PMID: 28811014
-
Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.J Manag Care Spec Pharm. 2015 Sep;21(9):754-68. doi: 10.18553/jmcp.2015.21.9.754. J Manag Care Spec Pharm. 2015. PMID: 26308223 Free PMC article.
-
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.CNS Drugs. 2021 Nov;35(11):1189-1205. doi: 10.1007/s40263-021-00861-6. Epub 2021 Oct 11. CNS Drugs. 2021. PMID: 34636025 Free PMC article. Review.
-
Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.CNS Drugs. 2021 May;35(5):469-481. doi: 10.1007/s40263-021-00815-y. Epub 2021 Apr 28. CNS Drugs. 2021. PMID: 33909272 Free PMC article.
Cited by
-
Preferences for Selecting and Initiating Long-Acting Injectable Antipsychotic Agents for the Treatment of Patients With Schizophrenia: Results From the US DECIDE Survey.Schizophr Bull Open. 2025 Jan 8;6(1):sgaf001. doi: 10.1093/schizbullopen/sgaf001. eCollection 2025 Jan. Schizophr Bull Open. 2025. PMID: 40110565 Free PMC article.
References
-
- Houghton N, Bascolo E, Cohen RR, Cruz Vilcarromero NL, Rodriguez Gonzalez H, Albrecht D, Koller TS, Fitzgerald J. Identifying access barriers faced by rural and dispersed communities to better address their needs: implications and lessons learned for rural proofing for health in the Americas and beyond. Rural Remote Health. 2023. Mar;23(1):7822. 10.22605/RRH7822 - DOI - PubMed
-
- Kane JM, Schooler NR, Marcy P, Correll CU, Achtyes ED, Gibbons RD, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020. Dec 1;77(12):1217-24. 10.1001/jamapsychiatry.2020.2076 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous